✨ Free AI Report
Ventyx Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ventyx Biosciences, Inc.
Company Research

Ventyx Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Lilly will acquire all outstanding shar...

Analyst-debate audio for Ventyx Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Ventyx Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Clinical-stage biotech with differentiated NLRP3 inhibitor platform being acquired by Lilly for inflammation-driven chronic...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Clinical-Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Ventyx Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Ventyx Biosciences, Inc. Overview

Pro stress-test →

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Lilly will acquire all outstanding shares at $14.00 per share in an all-cash transaction valued at approximately $1.2 billion, with the transaction expected to close in the first half of 2026.

Strategic Profile

Pro stress-test →

The company's expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, with extensive experience in clinical development allowing rapid progression through clinical trials. Lead portfolio includes NLRP3 inhibitors VTX2735 and VTX3232 in Phase 2 development, plus inflammatory bowel disease candidates tamuzimod and VTX958 that have completed Phase 2 trials.

Competitive Landscape

Pro stress-test →

Ventyx operates in clinical-stage biotech with 52 identified competitors including RedHill Biopharma. The company differentiates through oral NLRP3 inhibitors targeting inflammation-driven chronic diseases where limited treatment options exist. Acquisition by Lilly positions pipeline within a major pharma focused on inflammatory and cardiometabolic indications.

Industry Context

Ventyx Biosciences, Inc. operates in Biopharmaceuticals - Clinical-Stage Drug Development.

Key facts

Founded: 2018 · Headquarters: San Diego, United States · Market cap: $1.0B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Ventyx Biosciences, Inc..

  • Eli Lilly acquisition announced January 7, 2026 at $14 per share for ~$1.2 billion
  • VTX3232 demonstrates cardiovascular benefit in Phase 2 and completed Parkinson's biomarker studies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Lilly acquisition agreement announced at $14/share for ~$1.2B
  • November 2025VTX3232 Phase 2 data reported significant cardiovascular risk factor reductions
  • +1 moreTrack every material event for Ventyx Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Ventyx Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

JAK InhibitorsApproved treatments for autoimmune/inflammatory diseases with broader JAK pathway inhibition→GLP-1 TherapiesCardiometabolic risk management increasingly combined with targeted anti-inflammatories→RedHill BiopharmaClinical-stage developer in gastrointestinal and inflammatory diseases→

Compare Ventyx Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ventyx Biosciences, Inc. operates in Biopharmaceuticals - Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about Ventyx Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ventyx Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Ventyx Biosciences, Inc. do this quarter?”
“Is Ventyx Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Ventyx Biosciences, Inc. do?+
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Lilly will acquire all outstanding shar...
What is Ventyx Biosciences, Inc.'s Cyborg Score?+
Ventyx Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ventyx Biosciences, Inc.'s main competitors?+
Named competitors include JAK Inhibitors, GLP-1 Therapies, RedHill Biopharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Ventyx Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ventyx Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ventyx Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.